Regulatory Webinar Series


How to Develop an Effective Schedule of Events for a Research Protocol

So Many Procedures, So Little Time - How to Develop an Effective Schedule of Events for a Research Protocol. Presented by: Mike Fusakio, PhD; Nathan Hawk, BSPS; Samantha Sonoda, MS, CCRA; Lisa M. Tully, MA, CCRP, all affiliated with Cincinnati Children's Hospital Medical Center. Originally aired Dec. 2, 2020.

View or download slides


Single IRB (Institutional Review Board) Presentation & Panel Discussion

Single Institutional Review Board (IRB): Presentation & Panel Discussion. Features Nichelle Cobb, PhD, Smart IRB Director at University of Wisconsin-Madison. Panelists include James Cnota MD (Cincinnati Children's), Jeremy Corsmo, MPH (Cincinnati Children's), Pooja Khatri, MD, MSC (University of Cincinnati) and Mike Linke, PhD (University of Cincinnati). Originally aired Sept. 16, 2020.

View or download slides


Human Subject Research Protocols: If you write it (well), they will come

Helpful Tips and Tricks for Developing and Amending Protocols for the Rare Disease Clinical Research Network, presented By: Mike Fusakio PhD, Cincinnati Children's Hospital Medical Center. Originally aired June 30, 2020.

View or download slides

For Early Career Researchers


NIH Mentored Research (K) Career Development Awards for Clinician Researchers

NIH Mentored Research (K) Career Development Awards for Clinician Researchers, featuring Paula Gregory, PhD, Associate Dean for Faculty & Educational Development, UNTHSC Graduate School of Biomedical Sciences, with Debra Regier, MD, PHD, of Children's National Hospital, Principal Investigator of the Rare Disease Scholar's Program.

Diversity in Rare Disease Research


Race, ethnicity and racism in the nutrition literature: an update for 2020 imageRace, ethnicity and racism in the nutrition literature: an update for 2020.

Reviews the limitations of classifying research participants by race, and recommends a series of steps for authors, researchers and policymakers to consider.


Enhancing Diversity of Clinical Trial Populations Image

The U.S. Food and Drug Administration has published guidance on “Enhancing the Diversity of Clinical Trial Populations – Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry.” This guidance recommends approaches that sponsors of clinical trials intended to support a new drug application or a biologics license application can take to increase enrollment of underrepresented populations in their clinical trials.

Additional Resources


NIH Sharing Website NIH Scientific Data Sharing Website

A central portal for NIH sharing policies that offers resources to help address common questions, such as which NIH sharing policies apply to a particular research project, how to share and submit data, how to access data from NIH-supported repositories, and more.


Trial Innovation Network Trial Innovation Network

A collaborative initiative within the Clinical and Translational Science Awards (CTSA) Program that aims to execute clinical trials better, faster, and more cost-efficiently but, importantly, to be a national laboratory to study, understand, and innovate the process of conducting clinical trials.


Trial Innovation Network Toolkit Trial Innovation Network Toolbox

A central resource-sharing platform where recruitment and retention resources developed by CTSAs and reputable community health partners are provided as a free resource to the research community.


NIH Data Management image

The The NIH has released a Data Management and Sharing policy, which goes into effect January 25, 2023 and replaces the existing 2003 NIH Data Sharing Policy. The policy is updated to keep pace with scientific and technological advancements and emphasizes the NIH’s commitment to data management and sharing, which is seen as an integral piece to the conduct of research. A summary of the new policy can be found here.


FDA Screenshot FDA Drug Development Resources for the Rare Disease Community and More

Academic investigators, patient groups, and small or emerging pharmaceutical and biotechnology companies play a critical role in rare disease drug development and are often the sponsors for rare disease drug development, but they may lack regulatory experience. These resources will help bridge the gap between academic investigation and the regulatory aspects of drug development.

COVID-19 Resources


Screenshot of https://grants.nih.gov/grants/natural_disasters/corona-virus.htm Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding

A centralized information page that includes links to a variety of guidance, information, resources, FAQs and NIH funding opportunities relating to COVID-19, from the NIH Central Resource for Grants and Funding Information. Topics include:

  • An overview presentation and talking points (updated 7/17/2020)
  • Proposal submission and award management
  • Human subjects and clinical trials
  • Animal welfare
  • Peer review
  • FAQs (updated 7/2/2020)
  • Request for Information
  • Funding Opportunities
  • Funded Grants
  • Links to additional resources (NIH, CDC, WHO and “General information on NIH extramural response to natural disasters and other emergencies”)

Screenshot of https://grants.nih.gov/faqs#/covid-19.htmFrequently Asked Questions (FAQs)

Update 7/2/2020: All COVID-19 FAQs were reviewed and revised to align with NIH Implementation of OMB Memorandum M-20-26.


Screenshot of https://ncats.nih.gov/covid19-translational-approachNCATS: A Translational Approach to Addressing COVID-19

The National Center for Advancing Translational Sciences is supporting research activities spanning the translational science spectrum to address the novel coronavirus 2019 (SARS-CoV-2) and the disease it causes (COVID-19). Check the page for future updates. Topics include:

  • Research Activities - projects that are leveraging existing platforms and collaborations that are speeding research
  • Additional Resources - funding, updates from grantees and partners, and NIH and CDC COVID-19 resources